Loading...

SCND

SND

ASCENDIS PHARMA A

(ASND)

2025 6-K

Warrant Exercise Update

30 Mar '26

Annual Meeting Results

24 Mar '26

Positive Trial Results

17 Mar '26

Clinical Trial Results

16 Mar '26

Warrant Granting

11 Mar '26

FDA Approval Granted

2 Mar '26

Annual Meeting Notice

23 Feb '26

Financial Results Report

11 Feb '26

Warrant Grants

11 Feb '26

Warrant Grants

14 Jan '26

Strategic Roadmap Update

12 Jan '26

Clinical Trial Results

8 Jan '26

Warrant Exercise Update

30 Dec '25

Warrant Grants

10 Dec '25

FDA Update

25 Nov '25

Warrant Grants

12 Nov '25

Financial Results

12 Nov '25

Financial Results Report

12 Nov '25

Product Launch Announcement

22 Oct '25

Warrant Grants Announced

15 Oct '25

Marketing Application Filed

8 Oct '25

Warrant Exercise Update

30 Sep '25

Warrant Grants

10 Sep '25

Warrant Grants

13 Aug '25

Q2 Earnings Report

7 Aug '25

Financial Results Release

7 Aug '25

FDA Approval Announcement

28 Jul '25

Warrant Granting

9 Jul '25

Warrant Exercise Closure

27 Jun '25

Warrant Grants

11 Jun '25

Topline Data Report

9 Jun '25

Clinical Trial Results

9 Jun '25

FDA Acceptance Notification

2 Jun '25

Annual Meeting Outcomes

28 May '25

Warrant Granting

14 May '25

Financial Results Update

1 May '25

Financial Results Q1 2025

1 May '25

Annual Meeting Notice

29 Apr '25

Warrant Grants

9 Apr '25

New Drug Application

31 Mar '25

Warrant Exercise Update

28 Mar '25

IPO Announcement

20 Mar '25

Warrant Grants

12 Mar '25

Share Repurchase Program

12 Feb '25

Financial Results Announcement

12 Feb '25

Warrant Grants Update

12 Feb '25

Warrant Grants

15 Jan '25

Investor Presentation

13 Jan '25

Business Update

13 Jan '25

Warrant Exercise Update

30 Dec '24

Ascendis Collaboration

17 Dec '24

FDA Application Accepted

12 Dec '24

Warrant Granting

11 Dec '24

Quarterly Results

14 Nov '24

Financial Update

14 Nov '24

Warrant Grant Notification

13 Nov '24

Partnership Agreement

4 Nov '24

Warrant Grants

9 Oct '24

FDA Application Submitted

30 Sep '24

Warrant Exercise Closure

27 Sep '24

ADS Offering Summary

23 Sep '24

Trial Results Report

16 Sep '24

Trial Results Report

16 Sep '24

FDA Exclusivity Granted

11 Sep '24

Warrant Grant Details

11 Sep '24

Revenue Participation Agree...

3 Sep '24

Financial Results Report

3 Sep '24

Financial Report Update

3 Sep '24

Warrant Grants

14 Aug '24

FDA Approval Announcement

12 Aug '24

Warrant Grants

10 Jul '24

Warrant Exercise Closed

28 Jun '24

Warrant Grants Report

12 Jun '24

Annual Meeting Results

31 May '24

Warrant Grants

16 May '24

FDA Review Update

14 May '24

Financial Performance Update

2 May '24

Financial Results Report

2 May '24

Annual Meeting Notice

2 May '24

Regulatory Authorization

24 Apr '24

Warrant Grants

10 Apr '24

Warrant Exercises Completed

27 Mar '24

Warrant Grants

14 Mar '24

Management Change

29 Feb '24

Warrant Grants

14 Feb '24

Financial Results Released

7 Feb '24

Product Launch Announcement

31 Jan '24

Company Formation

29 Jan '24

Warrant Grants

10 Jan '24

Investor Meetings Notice

8 Jan '24

Corporate Milestones Update

8 Jan '24

Warrant Exercise Update

2 Jan '24

External Links:

SEC

On September 29, 2025, Ascendis Pharma A/S closed an exercise window for warrants, increasing their share capital by DKK 543,748, totaling DKK 61,695,211, with about 543,748 shares issued at approximately USD $97.45 each. This filing is significant for investors as it reflects capital changes and warrant exercises.

AI Assistant

ASCENDIS PHARMA A

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.